172 related articles for article (PubMed ID: 35829833)
1. Co-expression of High-mobility group box 1 protein (HMGB1) and receptor for advanced glycation end products (RAGE) in the prognosis of esophageal squamous cell carcinoma.
Li L; Beeraka NM; Xie L; Dong L; Liu J; Wang L
Discov Oncol; 2022 Jul; 13(1):64. PubMed ID: 35829833
[TBL] [Abstract][Full Text] [Related]
2. Verbascoside represses malignant phenotypes of esophageal squamous cell carcinoma cells by inhibiting CDC42 via the HMGB1/RAGE axis.
Ji M; Sun J; Zhao J
Hum Exp Toxicol; 2022; 41():9603271221127429. PubMed ID: 36112883
[TBL] [Abstract][Full Text] [Related]
3. Clinical Implications of High-mobility Group Box-1 (HMGB1) and the Receptor for Advanced Glycation End-products (RAGE) in Cutaneous Malignancy: A Systematic Review.
Nguyen AH; Detty SQ; Agrawal DK
Anticancer Res; 2017 Jan; 37(1):1-7. PubMed ID: 28011467
[TBL] [Abstract][Full Text] [Related]
4. The expression of high mobility group box 1 is associated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma.
Chuangui C; Peng T; Zhentao Y
Pathol Oncol Res; 2012 Oct; 18(4):1021-7. PubMed ID: 22544356
[TBL] [Abstract][Full Text] [Related]
5. Plasma miR-185 is decreased in patients with esophageal squamous cell carcinoma and might suppress tumor migration and invasion by targeting RAGE.
Jing R; Chen W; Wang H; Ju S; Cong H; Sun B; Jin Q; Chu S; Xu L; Cui M
Am J Physiol Gastrointest Liver Physiol; 2015 Nov; 309(9):G719-29. PubMed ID: 26316588
[TBL] [Abstract][Full Text] [Related]
6. Expression of HMGB1/RAGE protein in renal carcinoma and its clinical significance.
Qie GQ; Wang CT; Chu YF; Wang R
Int J Clin Exp Pathol; 2015; 8(6):6262-8. PubMed ID: 26261503
[TBL] [Abstract][Full Text] [Related]
7. Co-expression of RAGE and HMGB1 is associated with cancer progression and poor patient outcome of prostate cancer.
Zhao CB; Bao JM; Lu YJ; Zhao T; Zhou XH; Zheng DY; Zhao SC
Am J Cancer Res; 2014; 4(4):369-77. PubMed ID: 25057439
[TBL] [Abstract][Full Text] [Related]
8. Expression of receptor for advanced glycation end products (RAGE) is related to prognosis in patients with esophageal squamous cell carcinoma.
Tateno T; Ueno S; Hiwatashi K; Matsumoto M; Okumura H; Setoyama T; Uchikado Y; Sakoda M; Kubo F; Ishigami S; Shinchi H; Natsugoe S
Ann Surg Oncol; 2009 Feb; 16(2):440-6. PubMed ID: 19023628
[TBL] [Abstract][Full Text] [Related]
9. HMGB1 Promotes Lymphangiogenesis through the Activation of RAGE on M2 Macrophages in Laryngeal Squamous Cell Carcinoma.
Su C; Jia S; Ma Z; Zhang H; Wei L; Liu H
Dis Markers; 2022; 2022():4487435. PubMed ID: 35280439
[TBL] [Abstract][Full Text] [Related]
10. Research on the relationship between RAGE and its ligand HMGB1, and prognosis and pathogenesis of gastric cancer with diabetes mellitus.
Zhou Y; Liu SX; Zhou YN; Wang J; Ji R
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1339-1350. PubMed ID: 33629304
[TBL] [Abstract][Full Text] [Related]
11. The anti-tumor effects of evodiamine on oral squamous cell carcinoma (OSCC) through regulating advanced glycation end products (AGE) / receptor for advanced glycation end products (RAGE) pathway.
Ren L; Lou Y; Sun M
Bioengineered; 2021 Dec; 12(1):5985-5995. PubMed ID: 34477479
[TBL] [Abstract][Full Text] [Related]
12. Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma.
Lin L; Zhong K; Sun Z; Wu G; Ding G
J Cancer Res Clin Oncol; 2012 Jan; 138(1):11-22. PubMed ID: 21947243
[TBL] [Abstract][Full Text] [Related]
13. [Expression and clinical significance of HMGB1 and RAGE in cervical squamous cell carcinoma].
Hao Q; Du XQ; Fu X; Tian J
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):292-5. PubMed ID: 18788635
[TBL] [Abstract][Full Text] [Related]
14. Clinical Implication of the Relationship Between High Mobility Group Box-1 and Tumor Differentiation in Hepatocellular Carcinoma.
Ando K; Sakoda M; Ueno S; Hiwatashi K; Iino S; Minami K; Kawasaki Y; Hashiguchi M; Tanoue K; Mataki Y; Kurahara H; Maemura K; Shinchi H; Natsugoe S
Anticancer Res; 2018 Jun; 38(6):3411-3418. PubMed ID: 29848691
[TBL] [Abstract][Full Text] [Related]
15. Association of high mobility group BOX-1 and receptor for advanced glycation endproducts with clinicopathological features of haematological malignancies: a systematic review.
Nguyen AH; Bhavsar SB; Riley EM; Caponetti GC; Agrawal DK
Contemp Oncol (Pozn); 2016; 20(6):425-429. PubMed ID: 28239277
[TBL] [Abstract][Full Text] [Related]
16. Reduced stratifin expression can serve as an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma.
Ren HZ; Pan GQ; Wang JS; Wen JF; Wang KS; Luo GQ; Shan XZ
Dig Dis Sci; 2010 Sep; 55(9):2552-60. PubMed ID: 20108042
[TBL] [Abstract][Full Text] [Related]
17. High-mobility group box 1 protein modulated proliferation and radioresistance in esophageal squamous cell carcinoma.
Di X; He G; Chen H; Zhu C; Qin Q; Yan J; Zhang X; Sun X
J Gastroenterol Hepatol; 2019 Apr; 34(4):728-735. PubMed ID: 29968320
[TBL] [Abstract][Full Text] [Related]
18. Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas.
Sasahira T; Akama Y; Fujii K; Kuniyasu H
Virchows Arch; 2005 Apr; 446(4):411-5. PubMed ID: 15789216
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of high-mobility group A2: A novel independent indicator of poor prognosis in patients with esophageal squamous cell carcinoma.
Wei R; Shang Z; Leng J; Cui L
J Cancer Res Ther; 2016; 12(4):1291-1297. PubMed ID: 28169242
[TBL] [Abstract][Full Text] [Related]
20. Expression and Significance of High-Mobility Group Protein B1 (HMGB1) and the Receptor for Advanced Glycation End-Product (RAGE) in Knee Osteoarthritis.
Sun XH; Liu Y; Han Y; Wang J
Med Sci Monit; 2016 Jun; 22():2105-12. PubMed ID: 27320800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
